Lilly announces Zepbound ™ (Tirzepatide) has been launched in pharmacies in the United States

On December 5, 2023, Eli Lilly announced its injection Zepbound ™ Tirzepatide has been listed in American pharmacies. Zepbound is suitable for adults with obesity or overweight, hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease and other weight related diseases to reduce and maintain weight.

Following the approval by the US Food and Drug Administration (FDA) on November 8, 2023, obese patients can now purchase Zepbound in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) through prescription at retail and mail order pharmacies.

Rhonda Pacheco, Vice President of Eli Lilly diabetes and Obesity Group, said: "Today, for obese adult patients who have been looking for new treatments like Zepbound, it has turned a new page. We are glad to see that the market coverage continues to expand, allowing millions of Americans to use Zepbound.

Regarding Zepbound ™ (Tirzepatide)

Zepbound ™ injection has been approved by the FDA as an adjuvant medication for low calorie diets and increased physical activity, for long-term weight management in obese adults (BMI ≥ 30 kg/m ²) or overweight adults (BMI ≥ 27 kg/m ²) with at least one weight related comorbidity. Zepbound is the first and only FDA approved obesity treatment drug that activates GIP (glucose dependent insulinotropic polypeptide) and GLP-1 (glucagon like peptide-1) hormone receptors. Its function is to affect insulin release by activating these two hormone receptors, thereby helping to reduce weight.